DURHAM – Hatteras Venture Partners, one of the largest and most active venture capital funds based in North Carolina, has closed on the first $94 million of a new fund.
Hatteras announced the new fund, HVP VI, on Monday.
The target for the fund is $200 million.
As part of the new funding, Hatteras has promoted two of its executives to partner and added two additional staff.
“The pace and quality of our deal flow has grown tremendously during the past several years,” said Clay Thorp, co-founder and General Partner of Hatteras, in the announcement.
“With HVP VI, we will continue to partner with innovative, driven entrepreneurs to launch and build world-class health care companies, many of which will be based upon leading-edge research stemming from the renowned academic centers in the southeastern U.S. In addition, we will continue to leverage our expanding national network to co-invest in promising companies in other regions.”
Mike Dial and Jeff Terrell were both promoted to partner, Each had joined Hatteras as analysts.
“Mike and Jeff have proven themselves to be invaluable members of the Hatteras team,” said Robert Ingram, General Partner of Hatteras, in the annou8ncemented. “They will be key drivers in our funds’ performance going forward.”
New staff members are Ben Scruggs and Kseniva Simpson. Both have earned a Ph.D. Scruggs will work as an associated, Simpson as an analyst.
Hatteras investments include G1 Therapeutics, PhaseBio, Kymera, Rodin, Elligo Health Research and Ribometrix.
The firm has more than $500 million under management.
